Abstract | BACKGROUND: METHODS: Ninety consecutive patients undergoing primary angioplasty with coronary stenting were randomized in a sequential alternating fashion to standard abciximab treatment (ABCX) group, intracoronary adenosine distal to the occlusion ( ADO) group, or neither (CTRL) group. All patients underwent a clinical and echocardiographic follow-up at 1 and 6 months. The primary end point was the prevalence of 6-month left ventricular remodeling. RESULTS: Baseline clinical, echocardiographic, and angiographic characteristics were similar. Mean final corrected TIMI frame count was 17 +/- 9, 16 +/- 12, and 23 +/- 11 frames in ABCX, ADO, and CTRL patients, respectively (P = .002). Angiographic no-reflow was observed in 7%, 13%, and 17% of ABCX, ADO, and CTRL patients, respectively (P > .20). At 6 months, left ventricular remodeling occurred in 7%, 30%, and 30% of ABCX, ADO, and CTRL patients, respectively (P = .045), with a percent increase in end-diastolic volume of 5% +/- 13%, 15% +/- 15%, and 12% +/- 18% (P = .04). CONCLUSIONS:
|
Authors | Anna S Petronio, Marco De Carlo, Nicola Ciabatti, Giovanni Amoroso, Ugo Limbruno, Caterina Palagi, Vitantonio Di Bello, Maria F Romano, Mario Mariani |
Journal | American heart journal
(Am Heart J)
Vol. 150
Issue 5
Pg. 1015
(Nov 2005)
ISSN: 1097-6744 [Electronic] United States |
PMID | 16290987
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antibodies, Monoclonal
- Immunoglobulin Fab Fragments
- Adenosine
- Abciximab
|
Topics |
- Abciximab
- Adenosine
(administration & dosage)
- Angioplasty, Balloon, Coronary
- Antibodies, Monoclonal
(therapeutic use)
- Coronary Vessels
- Female
- Humans
- Immunoglobulin Fab Fragments
(therapeutic use)
- Male
- Middle Aged
- Ventricular Remodeling
|